Ultragenyx Pharmaceutical RARE Return on equity

Return on equity at other companies

Eli LillyLLY

102.4%+15.7pp

AmgenAMGN

91.5%-7.7pp

Ionis PharmaceuticalsIONS

-105.5%+336pp

Arrowhead ResearchARWR

-46.4%+341pp

Zevra Therapeutics, Inc.ZVRA

34.8%+31.3pp

RegenxbioRGNX

-137.6%-817pp

FAQ

What is Ultragenyx Pharmaceutical's return on equity?

Ultragenyx Pharmaceutical (RARE) reported return on equity of -325.6% in Q3 2025.

How has Ultragenyx Pharmaceutical's return on equity changed year-over-year?

Ultragenyx Pharmaceutical's return on equity decreased by 10.2% year-over-year, from -295.5% to -325.6%.

What is the long-term trend for Ultragenyx Pharmaceutical's return on equity?

Over 4 years (2020 to 2024), Ultragenyx Pharmaceutical's return on equity has grown at a 79.6% compound annual growth rate (CAGR), from -20.6% to -214.7%.

What does return on equity mean?

Trailing-twelve-month net income divided by average shareholders' equity (average of the start and end of the trailing-twelve-month window). Measures the profit generated on each dollar of shareholder capital.